- Barrons.com•44 minutes ago
Leerink's Geoffrey Porges and Bradley Canino cut shares of Gilead Sciences (GILD) to Market Perform from Outperform, arguing that they're "tired of waiting." They explain why: We are downgrading Gilead Sciences today to Market Perform, and reducing our price target from $112 to $94. This sizable change in price target is driven by our updated forecast for the company’s HCV business, about which we have long been cautious but have now turned outright bearish. This lower forecast will inevitably be associated with margin erosion, and we have lowered our EBIT margin forecast by 310-480bps in each year after 2016.
- TheStreet.com•3 hours ago
Here are Tuesday's top research calls, including upgrades for AutoZone and Eli Lilly, and downgrades for J.M. Smucker and Toll Brothers.
Gilead Sciences Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||79.11 x 800|
|Ask||79.12 x 200|
|Day's Range||78.86 - 79.88|
|52wk Range||76.67 - 111.11|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||6.93|
|Avg Vol (3m)||10,627,257|
|Dividend & Yield||1.88 (2.31%)|